Home / Health / Ozempic Lawsuits: Patients Claim Vision Damage
Ozempic Lawsuits: Patients Claim Vision Damage
22 Sep
Summary
- Patients allege GLP-1 drugs cause sudden vision loss and blindness.
- Lawsuits filed against makers of Ozempic, Wegovy, Zepbound, Mounjaro.
- Scientific evidence linking GLP-1 drugs to NAION is still mixed.
A growing number of lawsuits have been filed in the United States against Novo Nordisk and Eli Lilly, the manufacturers of widely prescribed GLP-1 medications such as Ozempic, Wegovy, Zepbound, and Mounjaro. These legal challenges stem from allegations that the drugs may cause a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION).
NAION is characterized by damage to the optic nerve, which can result in sudden vision loss, typically affecting one eye. While some patients have reported these severe outcomes, the scientific community and regulatory bodies are still investigating the potential link between GLP-1 agonists and NAION. Current evidence is considered mixed, with some international regulators acknowledging NAION as a very rare potential adverse effect.
Beyond the vision loss allegations, semaglutide, a key ingredient in many of these drugs, has a known range of side effects. Common issues include nausea, vomiting, diarrhea, constipation, and digestive discomfort. More serious, though less frequent, side effects can involve dehydration leading to kidney problems, gallbladder issues, pancreatitis, and alterations in blood sugar levels, especially when used with certain diabetes medications.
Despite the ongoing lawsuits and reported side effects, health authorities emphasize that patients should not stop taking their prescribed GLP-1 medications without consulting a healthcare professional. These drugs play a crucial role in managing type 2 diabetes and obesity, and abrupt cessation could have significant health consequences. Patients experiencing any sudden or worsening vision changes should seek immediate medical attention.
